You're describing a chemical compound with a long and somewhat complex name. Let's break it down and understand its potential importance:
**Structure and Properties:**
* **[1-[3-(4-methylphenoxy)propyl]-2-benzimidazolyl]methanol** is a relatively large organic molecule with a benzimidazole core.
* **Benzimidazole** is a heterocyclic compound with a five-membered ring containing nitrogen atoms.
* **4-methylphenoxy** is a phenyl group (benzene ring) with a methyl group attached and an oxygen atom linking it to the propyl group.
* **Propyl** is a three-carbon chain.
* **Methanol** is a simple alcohol with a methyl group attached to an oxygen atom.
**Potential Importance in Research:**
You are correct, this is a complex molecule, and its specific importance will depend on the research context. Here are some possible areas where this compound might be investigated:
* **Pharmacology and Medicinal Chemistry:** Benzimidazole derivatives are known to have a wide range of biological activities. They have been explored as potential:
* **Anti-cancer agents:** Some benzimidazoles have been found to inhibit the growth of cancer cells.
* **Anti-parasitic agents:** They are effective against parasites such as roundworms and tapeworms.
* **Anti-bacterial agents:** Benzimidazole-containing compounds can exhibit antimicrobial properties.
* **Anti-viral agents:** Some benzimidazoles have shown antiviral activity.
* **Materials Science:** The structure of this compound suggests potential applications in:
* **Organic electronics:** Benzimidazole derivatives can be used as building blocks for organic semiconductors and other electronic materials.
* **Polymer chemistry:** The molecule's structure could contribute to unique properties in polymers.
**Key Considerations for Research:**
* **Synthesis:** This compound is likely not commercially available. It would need to be synthesized in a laboratory using organic chemistry techniques.
* **Activity and Toxicity:** Thorough evaluation is needed to determine the compound's biological activity, potential toxicity, and any side effects.
* **Specificity and Selectivity:** Researchers would need to investigate the compound's target interactions and its specificity for particular pathways or molecules.
**To understand the specific importance of this compound, you'd need more context.** For example:
* What research group is studying it?
* What is the specific research question being investigated?
* What are the expected outcomes of the study?
Please provide more information if you can, and I'll be happy to help you further.
ID Source | ID |
---|---|
PubMed CID | 2945948 |
CHEMBL ID | 1345199 |
CHEBI ID | 108022 |
Synonym |
---|
[1-(3-p-tolyloxy-propyl)-1h-benzoimidazol-2- yl]-methanol |
BB 0219514 |
{1-[3-(4-methylphenoxy)propyl]-1h-benzimidazol-2-yl}methanol |
MLS000063116 |
smr000074314 |
CBKINASE1_016855 |
CBKINASE1_004455 |
CHEBI:108022 |
AKOS000272035 |
BRD-K91810283-001-01-3 |
STK865293 |
[1-[3-(4-methylphenoxy)propyl]benzimidazol-2-yl]methanol |
AF-399/42099822 |
HMS2304A13 |
615279-85-1 |
(1-(3-(p-tolyloxy)propyl)-1h-benzo[d]imidazol-2-yl)methanol |
F1791-0403 |
CHEMBL1345199 |
HMS3447E10 |
Q27186449 |
[1-[3-(4-methylphenoxy)propyl]-2-benzimidazolyl]methanol |
{1-[3-(4-methylphenoxy)propyl]-1h-1,3-benzodiazol-2-yl}methanol |
Z57300276 |
(1-(3-(4-methylphenoxy)propyl)-1h-benzimidazol-2-yl)methanol |
Class | Description |
---|---|
benzimidazoles | An organic heterocyclic compound containing a benzene ring fused to an imidazole ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.6310 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 19.9526 | 0.0072 | 15.7588 | 89.3584 | AID411 |
BRCA1 | Homo sapiens (human) | Potency | 12.5893 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 5.1735 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 22.7265 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.9811 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
geminin | Homo sapiens (human) | Potency | 20.5962 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 0.0032 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |